echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Clinical approval of yizhemeb tablets

    Clinical approval of yizhemeb tablets

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Approval document for clinical trials of drugs (SH: 600422): Announcement on obtaining the approval document for clinical trials of yizheimai tablets Recently, kunyao Group Co., Ltd

    (hereinafter referred to as "kunyao group" and "the company") received the approval document for clinical trials of drugs approved and issued by the State Food and Drug Administration (hereinafter referred to as "the State Food and Drug Administration"), and now the relevant information is announced as follows: 1

    Basic information of clinical approval document 1) drug name: yizheymaibu tablet 2) dosage form: tablet 3) Approval No.: 2016l06717 4) specification: 10mg 5) application items: domestic drug registration 6) Applicant: Kunming Pharmaceutical Group Co., Ltd

    7) acceptance No.: cyhs1501141 Yunnan 8) registration classification: original chemical category 6 9) Examination and approval conclusion: according to the drug administration law of the people's Republic of China and relevant regulations, after examination, the product meets the relevant requirements of drug registration, and agrees to carry out human bioequivalence (be) test

    The applicant shall complete the corresponding research work as required before the be test, during the be test and when applying for listing

    2、 Other information of drug research on July 1, 2015, the company first submitted an application for production application to the State Food and Drug Administration for yizheymaibu tablets, which was accepted

    On July 27, 2016, the State Food and Drug Administration approved the company to conduct human bioequivalence (be) test on the drug, and the company received the official approval document on August 11, 2016

    At present, the company has invested about 3 million yuan in R & D expenses

    The indications of ezem tablets developed by the company: primary hypercholesterolemia, homozygous familial hypercholesterolemia (hofh), homozygous sitosteronemia (or phytosteroemia)

    Cardiovascular disease is one of the most common and serious diseases endangering human health (especially the middle-aged and old people)

    Dyslipidemia is an important risk factor of atherosclerosis, coronary heart disease and other cardiovascular and cerebrovascular diseases

    Lipid regulating drugs can reduce the incidence and mortality of these diseases, and have a positive effect and profound influence on the prevention and treatment of cardiovascular diseases

    Currently, half of the country incidence of cholesterol lowering drugs is the statins, which are the mainstream of lipid regulating drugs market

    But as a combination of statins and their products, the market share of them is very steady

    With the rapid improvement of the living standard of the people, the incidence rate of hyperlipidemic patients is increasing linearly

    The incidence rate of cardiovascular diseases represented by dyslipidemia is obviously improved, and the domestic market is also increasing

    It will continue to expand

    Statins are widely used in our country, but the combination of ezemeb and statins has achieved good curative effect and good tolerance

    With the wide application of the combination, ezemeb will have a better market development prospect

    Foreign countries are preparing to market the compound preparation of ezemeb and statins, so it also provides an objective basis for the combination of ezemeb and statins in domestic clinic

    Relying on the huge market foundation of statins, the clinical space of ezemeb will be broad

    Yizheyi cereal (yishichun) was developed by Merck and Schering plough in cooperation

    It was approved by FDA in 2002, and then successively listed in European countries, Australia, Japan, South Korea and other countries

    On April 6, 2006, China approved the listing of imported yizhezi cereal in China

    Since its listing, it has been widely concerned and the sales prospect is very promising.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.